High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
Besides Wall Street's top-and-bottom-line estimates for Amgen (AMGN), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended June 2026.
Amgen has outperformed the broader market over the past year, and analysts are moderately optimistic about the stock’s prospects.
Amgen stock has nearly doubled investors' money over the past five years, yet current checks suggest a mixed picture where the Discounted Cash Flow (DCF) intrinsic value points to meaningful upside while market multiples look closer to fair. Amgen has delivered a 93.9% return over five years, which puts more focus on whether the current share price still leaves room relative to intrinsic value estimates. Confidence around Amgen's portfolio of established and late stage products can support...
Amgen (NasdaqGS:AMGN) received a positive opinion from the European Medicines Agency’s CHMP for an expanded Repatha indication in Europe. The recommendation covers use of Repatha to help reduce cardiovascular risk in high risk adults without a prior heart attack or stroke. The CHMP view is based on Phase 3 clinical data that showed a significant reduction in major adverse cardiovascular events. Amgen is a large biotech company with a focus on cardiometabolic, oncology and immunology...
In the closing of the recent trading day, Amgen (AMGN) stood at $387.42, denoting a -1.44% move from the preceding trading day.
EyePoint (EYPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will this pharma company become a new leader in the weight loss market?
Biogen’s growth portfolio, which includes one closely watched Alzheimer’s drug, is a bright spot in the second quarter.
Amgen (AMGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Wall Street is heading for another mixed session on Tuesday, with blue-chip gains offset by concerns about AI spending and Chinese competition weighing on some technology stocks. Dow Jones futures were up 317 points, or 0.6%, but the Nasdaq has been called 1% lower, with S&P 500 futures...
Recently, Zacks.com users have been paying close attention to Amgen (AMGN). This makes it worthwhile to examine what the stock has in store.
Most biotech investors treat FBT and IBB as two names for the same trade, but the structural differences buried in their index methodologies have produced shockingly different outcomes depending on where the market's momentum actually lives.
Most recently the leader of buzzy startup Tessera Therapeutics, Severino will look to improve the fortunes of a company facing emerging competition and declining sales for its prized gene therapy Elevidys.
The Dow Jones (^DJI) is packed with iconic businesses that have built strong brands and durable market positions. A select few continue to thrive, delivering solid returns and proving their resilience in an evolving market.
The decision to no longer seek approval of amlitelimab is the latest setback for a treatment once hailed as a future blockbuster. One analyst expects Sanofi to now pursue “strategic action” to boost its pipeline.
Looking back on therapeutics stocks’ Q1 earnings, we examine this quarter’s best and worst performers, including Amgen (NASDAQ:AMGN) and its peers.
Amgen (AMGN) concluded the recent trading session at $371.47, signifying a +1.48% move from its prior day's close.
Getting kicked off the Dow Jones Industrial Average sounds like a death sentence for a stock, but a handful of booted dividend giants went on to reward patient shareholders with stunning gains and steady income streams that index investors missed out on entirely.
Earlier in July, a federal judge blocked Colorado’s plan to impose a 70% price cap on Amgen’s blockbuster arthritis drug Enbrel, halting a significant state-level pricing move. The ruling eased concerns that aggressive state pricing limits on Enbrel could spread more widely, reducing a key regulatory overhang for Amgen’s portfolio. We’ll now explore how this legal setback to Colorado’s price cap effort could influence Amgen’s investment narrative and perceived long-term risks. Find 47...
Healthcare stocks declined late Wednesday afternoon, with the NYSE Healthcare Index down 0.4% and th
DIVO quietly hands retirees a monthly check from a portfolio of blue-chip giants, but a 150% payout ratio and a debt-laden pharma holding raise fair questions about what is actually backing that income.
A recent court decision blocking Colorado’s planned 70% price cap on Enbrel has removed a key regulatory overhang for Amgen (AMGN) and is refocusing attention on the stock’s earnings setup. See our latest analysis for Amgen. Beyond the court ruling, Amgen’s share price has quietly built positive momentum, with a 30 day share price return of 8.48% and year to date share price return of 11.78%, while the 1 year total shareholder return of 23.41% and 3 year total shareholder return of 70.66%...
Amgen is set to report Q2 earnings next month, with analysts expecting a single digit EPS decline.
For many cancers now, the standard treatment is chemotherapy plus an immunotherapy such as Merck Keytruda, the best-selling drug in the world. Many think it will pair two innovations: precisely-targeted chemo drugs known as antibody-drug conjugates, or ADCs, and augmented immunotherapies in the form of bispecific antibodies. Bispecific antibodies are being tested by Bristol Myers Squibb (with its partner BioNTech ), AstraZeneca and the biotech firm Summit Therapeutics ADCs have already rung up big sales for Astra, Pfizer Gilead Sciences and Roche Holding but Merck has a strong contender in development.
We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.
